Stoke Therapeutics Dividend
Dividend criteria checks 0/6
Stoke Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.8% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | -US$2.08 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14Stoke Therapeutics prices $97.5M public offering
Nov 20Stoke Therapeutics -2.7% AH, proposes public offering
Nov 18We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Nov 18Stoke Therapeutics EPS in-line
Nov 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if STOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STOK's dividend payments have been increasing.
Dividend Yield vs Market
| Stoke Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (STOK) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.8% |
| Analyst forecast in 3 Years (STOK) | 0% |
Notable Dividend: Unable to evaluate STOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate STOK's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as STOK has not reported any payouts.